ABSTRACT

BACKGROUND: Leukemia is a type of cancers that start in the bone marrow and produce a serious number of abnormal white blood cells. Bleeding and bruising problems, fatigue, fever, and an increased risk of infection are among symptoms of the disease. The main objective of this study is to identify the determinant of the progression rate of white blood cells among patients with chronic lymphocytic leukemia at Felege Hiwot Referral Hospital (FHRH), Bahir Dar, Ethiopia.

METHODS: A retrospective study design was conducted on 312 patients with chronic lymphocytic leukemia at FHRH, Bahir Dar, Ethiopia under treatment from 1 January 2017 to 31 December 2019. A linear mixed-effects model was considered for the progression of the white blood cell data.

RESULTS: The estimated coefficient of the fixed effect intercept was 84.68, indicating that the average white blood cell (WBC) count of the patients was 84.68 at baseline time by excluding all covariates in the model (P-value < .001). Male sex (β = 2.92, 95% confidence interval [CI] 0.58, 0.52), age (β = 0.17, 95% CI 0.08, 0.28), widowed/divorced marital status (β = 3.30, 95% CI 0.03, 6.57), medium chronic lymphocytic leukemia (CLL) stage (β = −4.34, 95% CI −6.57, −2.68), high CLL stage (β = −2.76, 95% CI −4.86, −0.67), hemoglobin (β = 0.09, 95% CI 0.02, 0.17), lymphocytes (β = 0.09, 95% CI 0.02, 0.17), platelet (β = 0.16, 95% CI 0.03, 0.29), red blood cell (RBC) (β = 0.17, 95% CI 0.09, 0.25), and follow-up time (β = 0.27, 95% CI 0.19, 0.36) were significantly associated with the average WBC count of chronic lymphocytic leukemia patients.

CONCLUSIONS: The finding showed that age, sex, lymphocytic, stage of chronic lymphocytic leukemia, marital status, platelet, hemoglobin, RBC, and follow-up time were significantly associated with the average WBC count of chronic lymphocytic leukemia patients. Therefore, health care providers should give due attention and prioritize those identified factors and give frequent counseling about improving the health of chronic lymphocytic leukemia patients.

KEYWORDS: Chronic lymphocytic leukemia, white blood cells, linear mixed model

Background

Leukemia is a type of cancers that start in the bone marrow and produce a serious number of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and swelling problems, feeling tired, fever, and an increased risk of infections. The diagnosis of CLL can only be established if the total number of B lymphocytes is above 5 × 10^9/L.\(^1\) Leukemia has 4 major types of categories, which are acute lymphocytic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloblastic leukemia (CML). Each main type of leukemia is named according to the type of cell that is affected (lymphoid cells or myeloid cells) and whether the disease begins with a mature or immature cell. Acute leukemia was rapidly growing and can overrun the body within a few weeks or months. In contrast, chronic leukemia is growing slowly and progressively worsening over the years.\(^2\) Globally, CLL affected about 904000 people in 2015 and resulted in 60 700 deaths. It is the most prevalent adult leukemia diagnosed in the western world, with an estimated 20110 new cases in 2017 and accounting for 25% to 30% of all leukemia.\(^1\) With an incidence of 4.1 per 10000 persons per year the disease displays a high heterogeneity in its clinical course, patients presenting with an indolent form often do not require treatment, whereas others experience a very aggressive course, leading to death within a month.\(^4\) In Africa, an estimated 119 386 people lived with chronic lymphocytic leukemia (CLL), a disease of the blood and marrow an estimated 15 720 people were expected to be diagnosed with CLL...
in 2014. In Ethiopia, the magnitude of chronic lymphocytic leukemia did not be well studied, but according to the early study of leukemia in adult Ethiopian Shambo in the 1990s in Tikur Anbessa (black lion), a specialized hospital in Addis Ababa chronic lymphocytic leukemia (CLL) accounts 21.1% of each of other types of leukemia. Chronic lymphocytic leukemia is an increasingly common problem and is associated with high morbidity and mortality in Ethiopia. Patients who died from CLL increase from time to time. However, there is a limited study to identify the determinants of chronic lymphocytic leukemia patients. The current CLL therapies are either symptomatic treatments like chemotherapy and immunotherapy that do not improve complete remission rates or effective treatments that target actual cancer but have excessive morbidity and toxicity rates. The etiology of CLL is unknown, no virus or oncogene is involved in its pathogenesis. Moreover, the optimal sequencing of drug combinations is unknown. Relationships between various chemicals, drugs, other environmental agents, and the development of disease are much less well established for CLL than for other forms of leukemia. However, there are few known risk factors for CLL include occupational causes by exposure to certain chemicals, radiation exposure, and tobacco users. There is a scarcity of research conducted previously about the progression of WBC among chronic lymphocytic leukemia patients in the study area. Therefore, this study was aimed to investigate determinants of progression of WBC of chronic lymphocytic leukemia patients. The current investigation was secondary.

Materials and Methods

Description of the study area and design

This study was conducted at Felege Hiwot Referral Hospital, Bahir Dar, northwest Ethiopia. The area is located 563 km from Addis Ababa, the capital city of the country. This hospital also serves as a referral hospital for the people who are referred from different districts. A retrospective study design was carried out to retrieve relevant information from the medical records of chronic lymphocytic leukemia patients to address the objective of the current investigation.

Source of population and data

The chronic lymphocytic leukemia patients were the source of the population for this study. The data was collected from the medical chart of chronic lymphocytic leukemia patients at the hospital under treatment from January 2017 to December 2019. The longitudinal were extracted from the patient’s chart which contains socio-demographic and clinical information of all chronic lymphocytic leukemia patients under follow-ups. Hence, the data for the current investigation was secondary.

Quality of data measurement

The data collection tool was pre-tested before the actual data collection to maintain data quality. Pre-testing is testing the validity, reliability, practicability and sensitivity of the tool before it is used for actual data collection. The completeness and consistency of questions related to secondary data were checked and pre-tested on 35 sample data and proper amendments were included after getting feedback from the pilot test. Data cleaning was performed daily and timely feedback was communicated to the data collectors.

Sample size

Patients who attended a minimum of 2 follow-up during the period 1 January 2017 to 31 December 2019 Bahir Dar, northwest Ethiopia was included in the study. Therefore, among the total of 1295 chronic lymphocytic leukemia patients registered from 1 January 2017 to 31 December 2019, only 312 chronic lymphocytic leukemia patients satisfy inclusion criteria and hence are included in this study. The longitudinal WBC count were measured every 4 months at 0 (baseline), 4, 8, 12, 16, 20, 24, 28, 32, and 36 month visits (so that $n = 10$), the sample sizes at the ten time points were 1295, 312, 281, 231, 182, 136, 104, 64, 40, and 17 patients respectively.

Variables in the Study

Response variables

The response variable was the longitudinal count of the progression of WBC among chronic lymphocytic leukemia patients. It is measured in WBC count $\times 10^3 / \mu L$.

Independent variables

The independent variables in the current investigation were socio-demographic variables and clinical factors.

- Socio-demographic variables and their codes
  - Sex (Female = 0 and Male = 1)
  - Place of residence (Urban = 0 and Rural = 1)
  - Age is a continuous variable measured in years.
  - Educational level (0 = illiterate and 1 = literate)
  - Marital status (0 = single, 1 = married, and 2 = widowed/divorced)

- Clinical variables
  - Platelet is a continuous variable measured in platelet count $\times 10^3 / \mu L$.
  - Hemoglobin is a continuous variable measured in g/dL.
  - Hematocrit is a continuous variable measured in percent.
  - Lymphocyte is a continuous variable measured in number / $\mu L$.
  - Red blood cell is a continuous variable measured in RBC count $\times 10^6 / \mu L$. 
• Stage of CLL (0 = low, 1 = medium, and 2 = high)
• Presence of anemia (0 = no and 1 = yes)

Operational definition
For most cancers, staging is the process of finding out how far the cancer has spread. Stages are often useful because they can help guide treatment and determine a person's outlook. Most types of cancer are staged based on the size of the tumor and how far the cancer has spread. Doctors separate the Rai stages into low, intermediate (medium), and high-risk groups when determining treatment options.12

Data processing and analysis
In this study, R 4.0.3 version software was considered for data analysis. A statistical decision was made at 5% of level of significance.

Statistical Models
Linear mixed-effect model
A linear mixed model is a parametric linear model for longitudinal or repeated measures data that quantifies the relationships between a continuous dependent variable and various predictor variables. It extends from the classical linear regression model that takes into account both fixed effect and random effect. The random effect contains subject-specific effects and the fixed effect contains the set of predictors that are fixed across the subjects or the same for all subjects. The fixed effect parameters describe the relationships of the predictors to the dependent variable for an entire population and random effects are specific to subjects within a population. Consequently, random effects are directly used in modeling the random variation in the dependent variable.13 The random effects are not only determining the correlation structure between observations on the same subject but also taking into account heterogeneity among subjects, due to unobserved characteristics.

The general linear mixed-effects model defined as
\[ y_i = X_i \beta + Z_i b_i + \epsilon_i \]
Where,
- \( y_i \) is the \( n_i \times 1 \) vector of repeated measurements for \( i^{th} \) subject
- \( \beta \) is a \( p \times 1 \) vector of the fixed effects parameter
- \( X_i \) is a \( n_i \times p \) known design matrix corresponding to fixed effects \( \beta \)
- \( b_i \) is a \( q \times 1 \) vector of random-effects parameters
- \( Z_i \) is a \( n_i \times q \) known design matrix corresponding to random effects \( b_i \)
- \( \epsilon_i \) is the \( n_i \times 1 \) vector of the error terms.

The corresponding assumptions for model are \( b_i \sim N(0, G) \) and \( \epsilon_i \sim N(0, R_i) \) where, \( G \) and \( R_i \) are the variance-covariance matrix for \( b_i \) and \( \epsilon_i \) respectively and \( R_i \) represents the diagonal matrix of \( \sigma^2 I_{n_i} \) with an \( n_i \times n_i \) identity matrix \( I_{n_i} \). The random effects are assumed to be independent of the error terms \( \epsilon_i \), which means \( \text{cov}(b_i, \epsilon_i) = 0 \). The assumption \( \text{var}(\epsilon_i) = \sigma^2 I \) can be relaxed by allowing to model non-constant variance or special within-group correlation structures.

Results
The data consists of 312 patients who were chronic lymphocytic leukemia patients and treated under chronic lymphocytic leukemia follow-up between 1st January 2017 up to 31st December 2019 at FHRH, Bahir Dar, Ethiopia (Table 1).

Assessment of normality assumption
We could observe that histogram of the original data seems to satisfy the assumption of normality. However, for the histogram of the log-transformed data, the assumption of normality was violated (Figure 1).

The model with the smallest Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) value of covariance structure. Therefore, an unstructured covariance structure was selected due to the smallest AIC and BIC compared to the remaining covariance structures (Table 2).

The random intercept and slope model allows the intercept and coefficient to vary randomly among individuals. That means the individual WBC count of chronic lymphocytic patients varies from visit to visit randomly. Therefore, the random intercept and slope model is a more parsimonious model for the linear mixed-effects model based on its lower values of AIC and BIC (Table 3).

Univariable analysis for linear mixed model
Univariable analysis was performed to see the effect of each covariate on the progression of white blood cells by using purposeful variable selection in linear mixed effect model analysis and to select variables to be included in the multivariable analysis. Based on univariable analysis except for residence, all predictors were candidate variables for multivariable analysis of linear mixed models at 25 % level of significance.

Multivariable analysis for linear mixed model
Multivariable analysis of the linear mixed model was done by using all significant covariates at univariable analysis. Table 4 displays the result of the final linear mixed model, the result showed that the predictor age, sex, marital status, hemoglobin, platelets, lymphocyte, stage of CLL, RBC, and follow-up time were significantly associated with the average WBC of chronic lymphocytes leukemia patients at a 5% level of significance.
The variability between patients was $100.20 \times 10^3 / \mu L$, while the variability between patients was $0.13 \times 10^3 / \mu L$, the correlation between intercept and slope was $-0.54 \times 10^3 / \mu L$, and the variability within patients was $118.81 \times 10^3 / \mu L$ (Table 4).

### Discussion

The main objective of this study was to identify factors that affect the progression of WBC among chronic lymphocytic leukemia patients at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia. In this study, the linear mixed-effects model for longitudinal WBC count was used. The assumption of normality was checked using the histogram by comparing the plot of original and log-transformed data of chronic lymphocytic leukemia patients. All plots of the original data indicate that there is no deviation from the normality assumption and no need for transformation. The data were analyzed using the linear mixed-effects model by incorporating subject-specific variability. In this study, the unstructured covariance structure and random intercept and slope model had a smaller AIC and BIC compared to other models.

For a year’s increase in age, the average WBC count of the patients was significantly increased by $0.17 \times 10^3 / \mu L$ ($P$-value $<.001$) keeping all variables constant. This indicates that the age of patients is positively associated with the average WBC count of chronic lymphocytic leukemia patients. This finding was consistent with other studies. The average WBC count of the male chronic lymphocytic leukemia patients was significantly higher by $2.92 \times 10^3 / \mu L$ ($P$-value $= .014$) compared to the female chronic lymphocytic leukemia patients keeping all other variables constant. This finding was in line with other studies.
Table 2. Comparison of covariance structure for linear mixed-effects model.

| COVARIANCE STRUCTURES | INFORMATION CRITERIA | AR (1) | UN  | CS  | TOEP |
|-----------------------|----------------------|-------|-----|-----|------|
|                       | −2 Res Log Likelihood| 6654.07| 6653.29| 6653.99| 6657.40 |
|                       | AIC (smaller is better) | 13341.08 | 13340.58 | 13342.58 | 13367.40 |
|                       | BIC (smaller is better) | 13441.90 | 13432.67 | 13440.09 | 13454.80 |

Table 3. Selection of random effects to be included in the linear mixed-effects model.

| MODEL | RANDOM EFFECT       | AIC       | BIC       | −2LOGLIKHOOD |
|-------|---------------------|-----------|-----------|--------------|
| 1     | Random intercept    | 13380.1   | 13387.5   | 13376.1      |
| 2     | Random slope        | 13570.2   | 13577.7   | 13566.2      |
| 3     | Random intercept and slope | 13361.0 | 13346.0 | 13338.0 |

Table 4. Result of the final linear mixed model for CLL patients.

| COVARIATES                        | ESTIMATE | ST. ERROR | 95% CI | P-VALUE |
|-----------------------------------|----------|-----------|--------|---------|
| Intercept                         | 84.68    | 4.02      | 76.78  | 92.56   | <.001*  |
| Sex (Ref = female)                |          |           |        |         |
| Male                              | 2.92     | 1.19      | 0.58   | 5.25    | .014*   |
| Age                               | 0.17     | 0.05      | 0.08   | 0.26    | <.001*  |
| Marital status (Ref = single)     |          |           |        |         |
| Married                           | 1.33     | 1.72      | -2.05  | 4.70    | .441    |
| Widowed/divorced                  | 3.30     | 1.67      | 0.03   | 6.57    | .048*   |
| CLL stage (Ref = low)             |          |           |        |         |
| Medium                            | -4.34    | 1.36      | -6.57  | -2.68   | .001*   |
| High                              | -2.76    | 1.07      | -4.86  | -0.67   | .010*   |
| Hemoglobin                        | 0.15     | 0.04      | 0.07   | 0.22    | <.001*  |
| Platelets                         | 0.09     | 0.04      | 0.02   | 0.17    | .016*   |
| Lymphocytes                       | 0.16     | 0.06      | 0.03   | 0.29    | .013*   |
| RBC                               | 0.17     | 0.06      | 0.09   | 0.25    | .002*   |
| Observation time                  | 0.27     | 0.04      | 0.19   | 0.36    | <.001*  |

| RANDOM EFFECTS | STD.DEV | 95% CI |
|----------------|---------|--------|
| Intercept (b_i0) | 10.01   | 8.79   | 11.41  |
| Observation time (b_i1) | 0.36    | 0.26   | 0.50   |
| Correlation (b_i0,b_i1) | -0.54   | -0.70  | -0.32  |
| Residual (ε_i)     | 10.90   | 8.60   | 12.01  |

Abbreviation: Ref, reference category. *Significance at 5% of level of significance.
The probable justification may be the females tied with work and less access to follow the treatment in Ethiopia. Due to this reason, the average WBC count of male chronic lymphocytic leukemia patients was higher as compared to the average WBC count of female chronic lymphocytic leukemia patients.

The average WBC count of the respondents whose marital status was widowed/divorced chronic lymphocytic leukemia patients was significantly lower by $4.34 \times 10^{3} / \mu L$ (P-value = .001) compared to the low stage of chronic lymphocytic leukemia patients keeping all other variables constant. The average WBC count of the medium stage of chronic lymphocytic leukemia patients was significantly lower by $2.76 \times 10^{3} / \mu L$ (P-value = .010) compared to the low stage of chronic lymphocytic leukemia patients keeping all other variables constant. This finding was consistent with another study. The probable explanation is that as the stage of CLL is increased, the average WBC count has decreased.

For a unit increase in hemoglobin, the average WBC count of the patients was significantly increased by $15 \times 10^{3} / \mu L$ (P-value < .001) keeping all variables constant. This indicates that the hemoglobin of patients is positively associated with the average WBC count of chronic lymphocytic leukemia patients. This finding was similar to another study. The result showed that patients with higher hemoglobin had better survival from leukemia disease. For a unit increase in platelets, the average WBC count of the patients was significantly increased by $0.09 \times 10^{3} / \mu L$ (P-value = .016) keeping all variables constant. This finding was similar to another study. The result showed that patients had significantly increased duration of watchful waiting. Persistently high levels of Platelets have been suggested to be associated with complications and not correlated with other risk factors. Platelet volume levels have been reported to be increased as a consequence of chronic lymphocytic leukemia patients.

For a unit increase in lymphocytes, the average WBC count of the patients was significantly increased by $0.16 \times 10^{3} / \mu L$ (P-value = .013) keeping all variables constant. This indicates that the lymphocytes of patients are positively associated with the average WBC count of chronic lymphocytic leukemia patients. This study was similar to another study. The result showed that preliminary evidence suggests that a higher neutrophil-lymphocyte ratio (NLR) may be an indicator of active ulcerative colitis.

For a unit increase in RBC, the average WBC count of the patients was significantly increased by $0.17 \times 10^{3} / \mu L$ (P-value = .002) keeping all variables constant. For a unit increase in follow-up time (observation time), the average WBC count of the patients was significantly increased by $0.27 \times 10^{3} / \mu L$ (P-value < .001) keeping all variables constant. This indicates that the visit of patients in the hospital increased, the progression of WBC among chronic lymphocytic leukemia patients would be improved.

## Conclusion

The main goal of the current study was to identify the determinants of the progression of WBC among chronic lymphocytic leukemia patients at FHRH, Bahir Dar, Ethiopia. The data were collected from 312 chronic lymphocytic leukemia patients of medical charts at the hospital under follow-up from 1 January 2017 to 31 December 2019. The linear mixed model analysis showed that the predictor sex, age, marital status, CLL stage, hemoglobin, platelets, lymphocytes, RBC, and follow-up time (visits) were significantly associated with the progression of WBC among chronic lymphocytic leukemia patients. Therefore, health care providers should give due attention and prioritize those identified factors and give frequent counseling about improving the health of chronic lymphocytic leukemia patients.

## Acknowledgements

The authors would like to thank the Amhara Region Health Bureau, Bahir Dar referral hospital and staff members at Felege Hiwot Referral Hospital for supporting the study by granting them access to their medical records. They would also like to extend their gratitude to the Bahir Dar University the Department of Statistics for carrying out the research.

## Author Contributions

GDA has led the overall activities of the research process such as drafted the proposal, did the analysis, wrote the results, and prepared the manuscript. MWM, AST, DBB, and MAK participated in editing, analysis, prepared and critically revised the manuscript for its scientific content. All authors read and approved the final manuscript.

## Data Availability Statement

Data available on request.

## Ethics Consideration

The authors got an ethical approval certificate from Bahir Dar University Ethical approval committee, Bahir Dar, Ethiopia with Ref# BDU/14/2020 to use the secondary data related to patients. The Ethical approval certificate obtained in this committee can be attached upon request. Since the data used in the current investigation was secondary, there was no verbal or written consent from the participants.

## ORCID iD

Mitiku Wale Muluneh [https://orcid.org/0000-0002-2413-8026](https://orcid.org/0000-0002-2413-8026)
REFERENCES

1. Furman RR, Sharman JP, Cootre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.
2. Reta C, Altamirano L, Gonzalez JA, et al. Correction: segmentation and classification of bone marrow cells using contextual information for medical diagnosis of acute leukemias. PLoS One. 2015;10:e0134066.
3. Gill J, Hughes ME. Primer on chronic lymphocytic leukemia: part I. J Nurs Pract. 2018;14:302-308.
4. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49-62.
5. Zhang Y, Eliav Y, Shin SU, et al. B lymphocyte inhibition of anti-tumor response depends on expansion of Trg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother. 2013;62:87-99.
6. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94:1266-1287.
7. Mariam DH, Haidar J. A brief overview of issues addressed by EJHD publications (including index). Ethip J Health Dev. 2018;14:302-308.
8. Ambelie YA, Demissie AF, Gebregziabher MG. Patients’ satisfaction and associated factors among private wing patients at Bahirdar Felege Hiwot Referral Hospital, North West Ethiopia. Sci J Public Health. 2014;2:417-423.
9. Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogeneous disease. Cancer Genet. 2013;206:49-62.
10. Muhammad SKR, Taneja A, Malipedi D, Master SR. Chronic Lymphocytic Leukemia. StatPearls; 2017.
11. Mulune MW, Tegegne AS. Determinants of intracranial pressure and time to blindness for glaucoma patients at Felege Hiwot Referral Hospital, Bahir Dar, Ethiopia: a comparison of separate and joint models. Cancer Inform. 2021;20:11769351211045975.
12. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25:42-59.
13. Saengseem P, Kantaananta N. Spatial time series forecasts based on Bayesian linear mixed models for rice yields in Thailand. Paper presented at: Proceedings of the International MultiConference of Engineers and Computer Scientists; March 12-14, 2014; Hong Kong.
14. Teshnizi SH, Taghi Ayatollahi SM. Comparison of cox regression and parametric models: application for assessment of survival of pediatric cases of acute leukemia in southern Iran. Asian Pac J Cancer Prev. 2017;18:981-985.
15. Mikolaska M, Averbuch D, Tissof F, et al. Fluoroquinolone prophylaxis in hematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Infect J. 2018;76:20-37.
16. Erdmann F, Katsch P, Zeeh H, Roman E, Lightfoot T, Schiötz J. Survival from childhood acute lymphoblastic leukemia in West Germany: does socio-demographic background matter? Eur J Cancer. 2014;50:1345-1353.
17. Hussien H, Siddhom I, Naga SA, et al. Outcome and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute, Egypt. J Pediatr Hematol Oncol. 2004;26:507-514.
18. Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329-335.
19. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431-1446.
20. Sucu M, Davutoglu V, Sari I, Ozer O, Aksoy M. Relationship between platelet indices and aortic valve sclerosis. Clin Appl Thromb Hemost. 2010;16:563-567.
21. Demir AK, Demirtas A, Kaya SU, et al. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kacihid J Med Sci. 2013;31:585-590.